{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T04:49:12Z","timestamp":1772081352232,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.clinbiochem.2021.08.001","type":"journal-article","created":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T01:32:14Z","timestamp":1628472734000},"page":"67-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins"],"prefix":"10.1016","volume":"97","author":[{"given":"Erica M.","family":"Fatica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula M.","family":"Ladwig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josiah D.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mindy C.","family":"Kohlhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Lust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa R.","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria A.V.","family":"Willrich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2021.08.001_b0005","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1182\/blood-2011-04-349175","article-title":"Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma","volume":"118","author":"Wadhera","year":"2011","journal-title":"Blood."},{"issue":"3","key":"10.1016\/j.clinbiochem.2021.08.001_b0010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.bbmt.2013.11.022","article-title":"Secondary monoclonal gammopathy of undetermined significance is frequently associated with high response rate and superior survival in patients with plasma cell dyscrasias","volume":"20","author":"Zou","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"5","key":"10.1016\/j.clinbiochem.2021.08.001_b0015","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/ajh.24319","article-title":"Clinical characteristics and outcomes in biclonal gammopathies","volume":"91","author":"Mullikin","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0020","doi-asserted-by":"crossref","first-page":"551","DOI":"10.4049\/jimmunol.140.2.551","article-title":"A double monoclonal IgG1 kappa and IgG2 kappa in a single myeloma patient. Variation in clonal products and therapeutic responses","volume":"140","author":"Goni","year":"1988","journal-title":"J. Immunol."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0025","doi-asserted-by":"crossref","unstructured":"Pizzolato, Bragantini, Bresciani, Pavlovsky, Chuba, Vidal, Rostagno, Ghiso, IgG1-\u03ba biclonal gammopathy associated with multiple myeloma suggests a regulatory mechanism, Br. J. Haematol. 102 (1998) 503\u2013508. 10.1046\/j.1365-2141.1998.00805.x.","DOI":"10.1046\/j.1365-2141.1998.00805.x"},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0030","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/ajcp\/aqy037","article-title":"Interference of therapeutic monoclonal antibodies with routine serum protein electrophoresis and immunofixation in patients with myeloma: frequency and duration of detection of daratumumab and elotuzumab","volume":"150","author":"Tang","year":"2018","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0035","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1373\/jalm.2019.029009","article-title":"Incidence and Management of Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy Monitoring","volume":"5","author":"Liu","year":"2020","journal-title":"J. Appl. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0040","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ymeth.2015.04.020","article-title":"Detecting monoclonal immunoglobulins in human serum using mass spectrometry","volume":"81","author":"Mills","year":"2015","journal-title":"Methods."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0045","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1373\/clinchem.2015.253740","article-title":"Comprehensive assessment of M-proteins using nanobody enrichment coupled to MALDI-TOF mass spectrometry","volume":"62","author":"Mills","year":"2016","journal-title":"Clin. Chem."},{"issue":"8","key":"10.1016\/j.clinbiochem.2021.08.001_b0050","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/ajh.24772","article-title":"The utility of MASS-FIX to detect and monitor monoclonal proteins in the clinic","volume":"92","author":"Milani","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0055","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41375-018-0194-x","article-title":"Assay to rapidly screen for immunoglobulin light chain glycosylation: a potential path to earlier AL diagnosis for a subset of patients","volume":"33","author":"Kumar","year":"2019","journal-title":"Leukemia."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0060","doi-asserted-by":"crossref","first-page":"e154","DOI":"10.1016\/j.clml.2019.09.257","article-title":"MEDI2228, a novel BCMA pyrrolobenzodiazepine antibody drug conjugate, overcomes drug resistance and synergizes with bortezomib and DNA damage response inhibitors in multiple myeloma","volume":"19","author":"Tai","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"6","key":"10.1016\/j.clinbiochem.2021.08.001_b0065","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/0002-9343(81)90326-0","article-title":"The Clinical Aspects of Biclonal Gammopathies Review of 57 Cases","volume":"71","author":"Kyle","year":"1981","journal-title":"Am J Med."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0070","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.rce.2014.07.003","article-title":"Biclonal gammopathies: Retrospective study of 47 patients","volume":"215","author":"Garc\u00eda-Garc\u00eda","year":"2015","journal-title":"Rev. Clin. Esp."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0075","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.leukres.2012.05.008","article-title":"Serum double monoclonal components and hematological malignancies: Only a casual association? Review of 34 cases","volume":"36","author":"Guastafierro","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0080","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1600-0609.1986.tb02658.x","article-title":"Double gammopathies: Incidence and clinical course of 20 patients","volume":"36","author":"Nilsson","year":"1986","journal-title":"Scand. J. Haematol."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0085","first-page":"135","article-title":"The double gammopathies: Clinical and immunological studies","volume":"65","author":"Riddell","year":"1986","journal-title":"Med. (United States)"},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0090","unstructured":"Antibody therapeutics approved or in regulatory review in the EU or US - The Antibody Society, (n.d.). https:\/\/www.antibodysociety.org\/resources\/approved-antibodies\/ (accessed April 1, 2021)."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10040219","article-title":"Complete depletion of daratumumab interference in serum samples from plasma cell myeloma patients improves the detection of endogenous M-proteins in a preliminary study","volume":"10","author":"Vakili","year":"2020","journal-title":"Diagnostics."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0100","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1373\/jalm.2018.026476","article-title":"Distinguishing Drug from Disease by Use of the Hydrashift 2\/4 Daratumumab Assay","volume":"3","author":"Thoren","year":"2019","journal-title":"J. Appl. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0105","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1515\/cclm-2015-1031","article-title":"Monitoring multiple myeloma patients treated with daratumumab: Teasing out monoclonal antibody interference","volume":"54","author":"McCudden","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0110","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/blood-2018-05-848986","article-title":"A universal solution for eliminating false positives in myeloma due to therapeutic monoclonal antibody interference","volume":"132","author":"Mills","year":"2018","journal-title":"Blood."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0115","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cca.2019.02.017","article-title":"MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins","volume":"492","author":"Moore","year":"2019","journal-title":"Clin. Chim. Acta."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinbiochem.2021.02.011","article-title":"Clearing drug interferences in myeloma treatment using mass spectrometry","author":"Kohlhagen","year":"2021","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0125","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1515\/cclm-2020-0581","article-title":"Automation and validation of a MALDI-TOF MS (Mass-Fix) replacement of immunofixation electrophoresis in the clinical lab","volume":"59","author":"Kohlhagen","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0130","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1515\/cclm-2015-1023","article-title":"Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixation","volume":"54","author":"Willrich","year":"2016","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0135","doi-asserted-by":"crossref","first-page":"E368","DOI":"10.1002\/ajh.25244","article-title":"MASS-FIX may allow identification of patients at risk for light chain amyloidosis before the onset of symptoms","volume":"93","author":"Kourelis","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"10","key":"10.1016\/j.clinbiochem.2021.08.001_b0140","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1038\/s41375-020-0940-8","article-title":"Multiple myeloma gammopathies N-glycosylation of monoclonal light chains on routine MASS-FIX testing is a risk factor for MGUS progression","volume":"34","author":"Dispenzieri","year":"2020","journal-title":"Leukemia."},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0145","doi-asserted-by":"crossref","unstructured":"S. Sidana, D.L. Murray, S. Dasari, R.S. Go, M.A. Willrich, M. Snyder, M. Kohlhagen, J.A. Lust, E. Muchtar, T. Kourelis, S.K. Kumar, A. Dispenzieri, M.A. Gertz, Glycosylation of Immunoglobulin Light Chains Is Highly Prevalent in Cold Agglutinin Disease, Blood. 134 (2019) 3510\u20133510. 10.1182\/blood-2019-121712.","DOI":"10.1182\/blood-2019-121712"},{"key":"10.1016\/j.clinbiochem.2021.08.001_b0150","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/labmed\/lmz006","article-title":"Demystifying biclonal gammopathy: A pathologist\u2019s perspective","volume":"50","author":"Sharma","year":"2019","journal-title":"Lab Med."}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912021002228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009912021002228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:57:14Z","timestamp":1757865434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009912021002228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":30,"alternative-id":["S0009912021002228"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2021.08.001","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2021.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}